Trial reportCancer science2014
A prospective, randomized study on hepatotoxicity of anastrozole compared with tamoxifen in women with breast cancer.
Trial report in Cancer science, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 34 citations in OpenAlex.
- Signal Detection and Temporal Analysis of Aromatase Inhibitor-Associated Hepatotoxicity: A Pharmacovigilance Study Integrating Bayesian Belief-Propagation Network and Frequentist Metrics.The international journal of medical robotics + computer assisted surgery : MRCAS · 2026Article
- Hepatic steatosis and fibrosis are associated with metabolic factors rather than endocrine therapy in breast cancer patients.Translational gastroenterology and hepatology · 2026Article
- Diabetes mellitus in breast cancer survivors: metabolic effects of endocrine therapy.Nature reviews. Endocrinology · 2024Review
- Increasing sustainability and reproducibility ofFrontiers in toxicology · 2024Article
- Tamoxifen use and potential effects on liver parenchyma: A long-term prospective transient elastographic evaluation.Hepatology communications · 2022Article
- Bone Safety Profile of Steroidal Aromatase Inhibitor in Comparison to Nonsteroidal Aromatase Inhibitors in Postmenopausal Women with Breast Cancer: A Network Meta-Analysis.Breast care (Basel, Switzerland) · 2022Article
- Effects of Tamoxifen vs. Toremifene on fatty liver development and lipid profiles in breast Cancer.BMC cancer · 2021Article
- Tamoxifen induces fatty liver disease in breast cancer through the MAPK8/FoxO pathway.Clinical and translational medicine · 2020Article
- Drug-induced liver injury after switching from tamoxifen to anastrozole in a patient with a history of breast cancer being treated for hypertension and diabetes.Therapeutic advances in chronic disease · 2020Article
- Cardiometabolic Effects of Endocrine Treatment of Estrogen Receptor-Positive Early Breast Cancer.Journal of the Endocrine Society · 2019Review
- High-Throughput Assessment of Mechanistic Toxicity of Chemicals in Miniaturized 3D Cell Culture.Current protocols in toxicology · 2019Article
- Effects of honey supplementation on safety profiles among postmenopausal breast cancer patients.Journal of Taibah University Medical Sciences · 2018Article
- High-content imaging assays on a miniaturized 3D cell culture platform.Toxicology in vitro : an international journal published in association with BIBRA · 2018Article
- Nonalcoholic fatty liver disease and mortality among cancer survivors.Cancer epidemiology · 2017Article
- The impact of Anastrazole and Letrozole on the metabolic profile in an experimental animal model.Scientific reports · 2015Article
- Observational
- Chemotherapy induced liver abnormalities: an imaging perspective.Clinical and molecular hepatology · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
30 authors at 18 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tamoxifen and anastrozole are widely used as adjuvant treatment for early stage breast cancer, but their hepatotoxicity is not fully defined. We aimed to compare hepatotoxicity of anastrozole with tamoxifen in the adjuvant setting in postmenopausal breast cancer patients. Three hundred and fifty-three Chinese postmenopausal women with hormone receptor-positive early breast cancer were randomized to anastrozole or tamoxifen after optimal primary therapy. The primary end-point was fatty liver disease, defined as a liver-spleen ratio <0.9 as determined using a computed tomography scan. The secondary end-points included abnormal liver function and treatment failure during the 3-year follow up. The cumulative incidence of fatty liver disease after 3 years was lower in the anastrozole arm than that of tamoxifen (14.6% vs 41.1%, P < 0.0001; relative risk, 0.30; 95% CI, 0.21-0.45). However, there was no difference in the cumulative incidence of abnormal liver function (24.6% vs 24.7%, P = 0.61). Interestingly, a higher treatment failure rate was observed in the tamoxifen arm compared with anastrozole and median times to treatment failure were 15.1 months and 37.1 months, respectively (P < 0.0001; HR, 0.27; 95% CI, 0.20-0.37). The most commonly reported adverse events were 'reproductive system disorders' in the tamoxifen group (17.1%), and 'musculoskeletal disorders' in the anastrozole group (14.6%). Postmenopausal women with hormone receptor-positive breast cancer receiving adjuvant anastrozole displayed less fatty liver disease, suggesting that this drug had a more favorable hepatic safety profile than tamoxifen and may be preferred for patients with potential hepatic dysfunction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.